Sunil J. Advani, MD Appointed Co-Leader of the Moores Cancer Center, Cancer Biology and Signaling Research Program
|
Congratulations to Dr. Sunil Advani who will join current Co-Leader, Jing Yang, PhD, at the helm of the Moores Cancer Biology and Signaling Program. Read More»
|
|
|
Hidden Hero Identified: Researchers Flip the Script on Liver Cancer
|
Scientists at the UC San Diego, School of Medicine investigated the role of activating transcription factor 4 (ATF4), a key mediator of the liver stress response. Despite being previously associated with advanced liver cancer, ATF4 was found to protect the liver against hepatocyte death and subsequent tumor formation. This unexpected result could inspire new clinical strategies for preventing liver disease and cancer. Read More»
|
NIH Grantwriting Training Now Available
|
UC San Diego is piloting a 1-year institutional membership to access free, virtual, self-directed courses on NIH grantspersonship and writing from the Bouvier Grant Group.
The course library is now open, and you are invited to take a look. Simply register with an @ucsd.edu email address via this link: https://bouviergrant.com/NIHLibrary/UCSD2023. Detailed instructions for getting started can be found on the Research Development website. Visit Site»
|
|
|
June 13, 2023 | 12:00 p.m.
Leichtag Biomedical Research Building, Room 107 and Zoom
|
June 16, 2023 | 12:00 p.m.
Leichtag Biomedical Research Building, Room 107 and Zoom
|
| |
NCI Cancer Prevention Fellowship Program
|
Applications for this postdoctoral fellowship program are open through August 1, 2023.
|
|
Applications for KL2 Mentored Career Development Award Now Open!
|
The ACTRI KL2 award is a mentored career development award that provides up to $120K toward salary, plus benefits, along with $25K per year in research funds. Successful applicants will receive up to 3 years of support. Applications for this program are open through August 15, 2023.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Cancer Research UK and the National Cancer Institute have released nine new challenges as part of their Cancer Grand Challenges funding opportunities: Ageing and Cancer, Cancer Cell Plasticity, Cancer Inequities, Chemotherapy-induced Neurotoxicities, Early-onset Cancers, Obesity, Physical Activity and Cancer, Retrotransposable Elements, Solid Tumors in Children, and T-cell Receptors.
Deadline: Thursday, June 22, 2023
|
This award will provide $100K in direct costs for 3 years. No part of the award may cover institutional overhead or other indirect costs.
Deadline: Tuesday, June 27, 2023
|
This award is for the next generation of creative thinkers with "high-risk/high-reward" ideas that have the potential to improve our understanding of and/or approaches to the prevention, diagnosis, and treatment of cancer. This award will fund early career researchers who have an innovative idea yet lack sufficient preliminary data to obtain traditional funding.
Deadline: Thursday, July 6, 2023
|
This NOSI will enable current NCI grant awardees or cooperative agreement program participants to collaborate with NCI CAP-IT Specialized Centers to support CAP-IT Program research. Collaborations should be proposed by investigators who are not currently CAP-IT Center investigators and whose research scope, interests, and activities, as specified in the parent awards, serve CAP-IT Program research objectives. Potential applicants are encouraged to contact the NCI Program Director to discuss the planned collaboration and application.
Deadline: Thursday, July 6, 2023
|
The goal of these Research Grants and Fellowships Programs is to identify and provide funding for innovative projects that exhibit the potential to make substantial contributions to cancer prevention and early detection. The Prevent Cancer Foundation defines cancer prevention as the “reduction of cancer incidence through research, education, and early detection.” Both Research Grants and Fellowships Programs will be awarded for 2 years at $50,000 per year, for a total of $100,000.
Deadline: Tuesday, July 11, 2023
|
|
|
Nature
Farhoud Faraji, Robert Saddawi-Konefka (Cancer Biology and Signaling), Zhiyong Wang, Alexander T. Wenzel, Miranda J. Song, Lauren M. Clubb, Hannah Carter (Structural and Functional Genomics), Jill P. Mesirov (Structural and Functional Genomics), and J. Silvio Gutkind (Cancer Biology and Signaling)
|
Cancer Discovery
Michael J. Dennis (Solid Tumor Therapeutics)
|
JAMA Oncology
Andrea Z. LaCroix (Cancer Control Program)
|
Molecular Cancer
Kun-Liang Guan (Cancer Biology and Signaling)
|
|
|
R3767-ONC-2011: A Phase III Trial of Fianlimab (REGN3767, antiLAG3) Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
|
PI: Gregory Daniels
NCT: NCT05352672
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@health.ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|
